Shandong Zhongzaisheng Biotechnology Co., Ltd. (formerly Jining Zhongzaisheng Huahui Pharmaceutical Technology Co., Ltd.) was established in March 2015 with a registered capital of 77 million yuan. It is a branch of Zhongzaisheng Environmental Technology Co., Ltd., a wholly-owned subsidiary established in Shandong Province by China Recycling Resources Development Co., Ltd.

The company is located in the Zoucheng Industrial Park in Shandong Province, covering an area of 99 acres with a building area of 28,000 square meters. It has 8 production and auxiliary workshops, and 17 supporting units including a R&D center and a quality inspection center. The company is primarily engaged in the research, development, production, and sales of pharmaceutical intermediates. It boasts a comprehensive quality management system, high-standard analytical testing laboratories, and a first-class management and operations team in China. Its products include sulbactam acid, triphenylchloromethane, pyridine hydrochloride, and others, covering pharmaceutical intermediates for anti-infective, anti-HIV, anti-tumor, and cardiovascular categories. The company currently has 210 employees, including 41 R&D personnel, accounting for 20% of the total workforce, with 12 holding intermediate or senior professional titles.

The company consistently adheres to a "people-oriented" safety production philosophy, utilizing advanced DCS control systems to achieve automation in the production process, ensuring precise, safe, and efficient process control. It has established a pharmaceutical intermediate R&D platform and a multifunctional pilot workshop capable of conducting various unit reactions, co-line batch incubation, and producing multiple varieties of high-value-added products. An open R&D system has been built, actively promoting industry-university-research collaboration. The company has already connected with multiple universities, research institutes, and renowned pharmaceutical companies,打通了研發(fā)、生產(chǎn)和銷售的渠道。

Embracing the development philosophy of "reduction, recycling, and resource utilization," the company employs internationally advanced technologies and equipment such as MVR evaporation systems, MBR membrane bioreactor technology, electrocatalytic oxidation technology, and UASB anaerobic tanks. This enables the comprehensive extraction and utilization of all wastewater, dedicated recovery of all auxiliaries, and recycling of all raw materials.

Adhering to the business principle of "market-oriented, service-focused, quality for survival, technology for development, and innovation-driven," the company strives to build a "safe, environmentally friendly, efficient, and standardized" pharmaceutical intermediate R&D platform and production base, committed to becoming a leader in the domestic pharmaceutical intermediate industry.